Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Acadia Pharmaceuticals Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Acadia Pharmaceuticals Inc is a mid-cap company with a market capitalization of $3.29B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For ACAD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 37.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 33.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ACAD included.
Follow ACAD free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | ACAD | Rank |
|---|---|---|
| Market Cap | $3.29B | 60/60 |
| P/E Ratio | 8.24x | 29/33 |
| P/B Ratio | 2.52x | 39/42 |
| EPS | $2.32 | – |
| Book Value/Share | $7.58 | – |
| Revenue/Share | $6.61 | – |
| FCF/Share | $0.85 | – |
| Metric | ACAD | Rank |
|---|---|---|
| ROE | 29.1% | 9/38 |
| ROA | 21.8% | 5/43 |
| ROIC | 6.2% | 21/46 |
| Gross Margin | 91.1% | 7/36 |
| Operating Margin | 7.6% | 23/39 |
| Net Margin | 33.4% | 7/35 |
| EBT Margin | 10.7% | 25/46 |
| Tax Rate | -213.5% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
| Metric | ACAD | Rank |
|---|---|---|
| Current Ratio | 3.39x | 25/59 |
| Quick Ratio | 3.09x | 11/44 |
| D/E Ratio | 0.33x | 34/48 |
| Financial Leverage | 1.33x | 33/48 |
| Working Capital | $863M | 31/59 |
| Metric | ACAD | Rank |
|---|---|---|
| Operating Cash Flow | $160M | 31/59 |
| Free Cash Flow | $146M | 26/50 |
| Capital Spending | -$15M | 20/50 |
| OCF Growth YoY | -14.7% | 26/34 |
| FCF/Sales | 12.8% | 26/42 |
| CapEx/Sales | 1.3% | 30/42 |
| Metric | ACAD | Rank |
|---|---|---|
| Asset Turnover | 0.65x | 13/40 |
| Receivables Turnover | 7.6x | 9/38 |
| Inventory Turnover | 0.9x | 28/36 |
| Fixed Assets Turnover | 66.6x | 11/41 |
| Days Sales Outstanding | 48 days | 30/38 |
| Days Inventory | 393 days | 9/36 |
| Payables Period | 161 days | 13/26 |
| Cash Conversion Cycle | 280 days | 9/24 |
| Metric | ACAD | Rank |
|---|---|---|
| Total Revenue | $1.14B | 30/46 |
| Operating Income | $86M | 27/51 |
| Net Income | $380M | 20/46 |
| R&D Expense | $331M | 38/58 |
| SG&A Expense | $620M | 31/41 |
| Cost of Goods Sold | $101M | 30/37 |
| Metric | ACAD | Rank |
|---|---|---|
| Shares Outstanding | 172M | – |
| Net Income Growth | 71.3% | 5/19 |
| EPS Growth | 75.8% | 7/25 |
| Total Current Assets | $1.22B | 70.2% of assets |
| Cash & Short-term Investments | $385M | 22.1% of assets |
| Accounts Receivable | $151M | 8.6% of assets |
| Inventory | $109M | 6.2% of assets |
| Total Liabilities | $436M | 25.0% of assets |
| Short-term Debt | $317M | 18.2% of assets |
Companies classified under the same SEC industry code as Acadia Pharmaceuticals Inc (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| ACAD Acadia Pharmaceuticals Inc | ▲ | $3.29B |
| LLY Eli Lilly & Co | ▼ | $1.18T |
| JNJ Johnson & Johnson | ▼ | $615.87B |
| ABBV Abbvie Inc. | ▼ | $504.37B |
| MRK Merck & Co., Inc. | ▶ | $360.08B |
| NVS Novartis Ag | ▼ | $287.41B |
| AZN Astrazeneca Plc | ▼ | $256.39B |
| ABT Abbott Laboratories | ▼ | $182.39B |
| NVO Novo Nordisk A S | ▼ | $172.56B |
| PFE Pfizer Inc | ▼ | $168.60B |
| VRTX Vertex Pharmaceuticals Inc / Ma | ▶ | $126.66B |
| BMY Bristol Myers Squibb Co | ▼ | $122.05B |
| GSK Gsk Plc | ▼ | $100.46B |
| SNY Sanofi | ▼ | $100.12B |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $81.76B |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $61.45B |
| TEVA Teva Pharmaceutical Industries Ltd | ▼ | $48.36B |
| ONC Beone Medicines Ltd. | ▲ | $41.96B |
| ZTS Zoetis Inc. | ▼ | $32.80B |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $31.02B |
| RPRX Royalty Pharma Plc | ▶ | $26.88B |
| ROIV Roivant Sciences Ltd. | ▲ | $24.22B |
| GMAB Genmab A/S | ▶ | $23.80B |
| UTHR United Therapeutics Corp | ▼ | $22.87B |
| VTRS Viatris Inc | ▼ | $21.43B |
| INSM Insmed Inc | ▶ | $21.02B |
| ASND Ascendis Pharma A/S | ▶ | $14.85B |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.65B |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.98B |
| CORT Corcept Therapeutics Inc | ▲ | $11.91B |
| ELAN Elanco Animal Health Inc | ▶ | $11.77B |
| SMMT Summit Therapeutics Inc. | ▲ | $11.67B |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.91B |
| BMRN Biomarin Pharmaceutical Inc | ▶ | $10.58B |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.39B |
| CYTK Cytokinetics Inc | ▲ | $8.61B |
| TGTX Tg Therapeutics, Inc. | ▶ | $8.56B |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.33B |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.23B |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $7.90B |
| ABVX Abivax S.A. | ▼ | $7.74B |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.14B |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.05B |
| ALKS Alkermes Plc. | ▲ | $6.92B |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.75B |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.13B |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.13B |
| RYTM Rhythm Pharmaceuticals, Inc. | ▲ | $5.93B |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.89B |
| BLTE Belite Bio, Inc | ▲ | $5.62B |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.20B |
| COGT Cogent Biosciences, Inc. | ▲ | $5.12B |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.94B |
| ORKA Oruka Therapeutics, Inc. | ▲ | $4.76B |
| ERAS Erasca, Inc. | ▲ | $4.68B |
| MANE Veradermics, Inc | ▲ | $4.55B |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.44B |
| EWTX Edgewise Therapeutics, Inc. | ▲ | $4.04B |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.03B |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $3.83B |
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals' First Quarter 2019 Financial Results Conference Call. My name is Shannon and I will be your coordinator for today. [Operator ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals Second Quarter ...
Our AI ranks Acadia Pharmaceuticals Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For ACAD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 37.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 33.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Acadia Pharmaceuticals Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, ACAD included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.